BioRestorative Therapies, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
25.5M
on 2026-03-31, from 6.77M on 2024-03-31 10-Q ↗
a raise that quarter, at its price
Newest
None
No S-3 or F-3 shelf on file in the last 30 months.
$1.0M
Rodman & Renshaw, agreement of 2025-10-06. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Cash
1.2 quarters
$3.6M on 2026-03-31 ÷ $3.0M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-02-13 | Public offering | not read | $0.35 | $5.0M | 424B4 ↗ |
| 2025-10-06 | Public offering | 678,125 | $1.84 | $1.1M | 424B5 ↗ |
| 2025-10-06 | Registered direct offering | 678,125 | $1.60 | $1.1M | 8-K ↗ |
Also on file: up to $1.0M promissory note agreed 2026-06-10 8-K ↗ · a 1-for-20 reverse split, 2026-09-02 8-K ↗